Skip to search formSkip to main contentSkip to account menu

Myocet

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Although doxorubicin (DXR) has been on the market for many years as an anti-cancer drug, a number of serious dose-limiting… 
2012
2012
Despite the success in treating the majority of children with newly diagnosed acute leukemia, children with relapsed or… 
2011
2011
Background: Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic… 
Review
2004
Review
2004
Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable… 
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To ascertain the efficacy and tolerability of non-pegylated liposomal doxorubicin (Myocet) and epirubicin combined with… 
Review
2004
Review
2004
Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles… 
Review
2004
Review
2004
Conventional anthracyclines are active against many tumor types, but cardiotoxicity related to the cumulative dose may limit… 
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for…